IGF2BP1 Promotes Multiple Myeloma with Chromosome 1q Gain Via Increasing CDC5L Expression in an m6A-Dependent Mannery

被引:0
|
作者
Xu, Jiadai [1 ]
Liu, Peng [2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Hematol, Shanghai, Peoples R China
关键词
D O I
10.1182/blood-2023-185888
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:2
相关论文
共 35 条
  • [1] IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner
    Xu, Jiadai
    Wang, Yawen
    Ren, Liang
    Li, Panpan
    Liu, Peng
    GENES & DISEASES, 2025, 12 (01)
  • [2] Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner
    Shi, Jiajun
    Zhang, Qianyi
    Yin, Xi
    Ye, Jiahui
    Gao, Shengqing
    Chen, Chen
    Yang, Yaxuan
    Wu, Baojuan
    Fu, Yuping
    Zhang, Hongmei
    Wang, Zhangding
    Wang, Bo
    Zhu, Yun
    Wu, Hongyan
    Yao, Yongzhong
    Xu, Guifang
    Wang, Qiang
    Wang, Shouyu
    Zhang, Weijie
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (02): : 449 - 464
  • [3] The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer
    Schott, Annekatrin
    Simon, Theresa
    Muller, Simon
    Rausch, Alexander
    Busch, Bianca
    Glass, Markus
    Misiak, Danny
    Dipto, Mohammad
    Elrewany, Hend
    Peters, Lara Meret
    Tripathee, Sunita
    Ghazy, Ehab
    Mueller, Florian
    Rolnik, Robin Benedikt
    Lederer, Marcell
    Hmedat, Ali
    Vetter, Martina
    Wallwiener, Markus
    Sippl, Wolfgang
    Huettelmaier, Stefan
    Bley, Nadine
    NAR CANCER, 2025, 7 (01):
  • [4] IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression
    Zhang, Lin
    Wan, Yicong
    Zhang, Zihan
    Jiang, Yi
    Gu, Zhiyue
    Ma, Xiaoling
    Nie, Sipei
    Yang, Jing
    Lang, Jinghe
    Cheng, Wenjun
    Zhu, Lan
    THERANOSTICS, 2021, 11 (03): : 1100 - 1114
  • [5] FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma
    Wang, Chong
    Li, Lingling
    Li, Mengya
    Wang, Weiqiong
    Jiang, Zhongxing
    CANCER GENE THERAPY, 2023, 30 (04) : 622 - 628
  • [6] FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma
    Chong Wang
    Lingling Li
    Mengya Li
    Weiqiong Wang
    Zhongxing Jiang
    Cancer Gene Therapy, 2023, 30 : 622 - 628
  • [7] HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
    Jiang, Fengjie
    Tang, Xiaozhu
    Tang, Chao
    Hua, Zhen
    Ke, Mengying
    Wang, Chen
    Zhao, Jiamin
    Gao, Shengyao
    Jurczyszyn, Artur
    Janz, Siegfried
    Beksac, Meral
    Zhan, Fenghuang
    Gu, Chunyan
    Yang, Ye
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [8] HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
    Fengjie Jiang
    Xiaozhu Tang
    Chao Tang
    Zhen Hua
    Mengying Ke
    Chen Wang
    Jiamin Zhao
    Shengyao Gao
    Artur Jurczyszyn
    Siegfried Janz
    Meral Beksac
    Fenghuang Zhan
    Chunyan Gu
    Ye Yang
    Journal of Hematology & Oncology, 14
  • [9] IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner
    Mueller, Simon
    Glass, Markus
    Singh, Anurag K.
    Haase, Jacob
    Bley, Nadine
    Fuchs, Tommy
    Lederer, Marcell
    Dahl, Andreas
    Huang, Huilin
    Chen, Jianjun
    Posern, Guido
    Huettelmaier, Stefan
    NUCLEIC ACIDS RESEARCH, 2019, 47 (01) : 375 - 390
  • [10] Interaction of PHGDH with IGF2BP1 facilitates m6A-dependent stabilization of TCF7L2 mRNA to confer multidrug resistance in gastric cancer
    Chen, Shuyi
    Li, Tingyu
    Liu, Dan
    Liu, Yi
    Long, Zhaobo
    Wu, Ying
    Zhong, Yue
    Zhao, Jun
    Wu, Tong
    He, Wenfang
    Cao, Tianyu
    Fan, Daiming
    Wu, Kaichun
    Lu, Yuanyuan
    Zhao, Xiaodi
    ONCOGENE, 2025,